Literature DB >> 23148372

Distinct epigenetic mechanisms distinguish TMPRSS2-ERG fusion-positive and -negative prostate cancers.

Joshi J Alumkal1, James G Herman.   

Abstract

This issue of Cancer Discovery features an article that describes distinct epigenetic mechanisms that operate in TMPRSS2-ERG fusion-negative prostate cancers. This finding clarifies molecular features of these TMPRSS2-ERG fusion-negative tumors and may have implications for how to treat this prostate cancer subtype. ©2012 AACR.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23148372      PMCID： PMC3661413          DOI： 10.1158/2159-8290.CD-12-0392

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  15 in total

1.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

Authors:  Scott A Tomlins; Daniel R Rhodes; Sven Perner; Saravana M Dhanasekaran; Rohit Mehra; Xiao-Wei Sun; Sooryanarayana Varambally; Xuhong Cao; Joelle Tchinda; Rainer Kuefer; Charles Lee; James E Montie; Rajal B Shah; Kenneth J Pienta; Mark A Rubin; Arul M Chinnaiyan
Journal:  Science       Date:  2005-10-28       Impact factor: 47.728

2.  An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.

Authors:  Jindan Yu; Jianjun Yu; Ram-Shankar Mani; Qi Cao; Chad J Brenner; Xuhong Cao; Xiaoju Wang; Longtao Wu; James Li; Ming Hu; Yusong Gong; Hong Cheng; Bharathi Laxman; Adaikkalam Vellaichamy; Sunita Shankar; Yong Li; Saravana M Dhanasekaran; Roger Morey; Terrence Barrette; Robert J Lonigro; Scott A Tomlins; Sooryanarayana Varambally; Zhaohui S Qin; Arul M Chinnaiyan
Journal:  Cancer Cell       Date:  2010-05-18       Impact factor: 31.743

3.  Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation.

Authors:  Stefan T Börno; Axel Fischer; Martin Kerick; Maria Fälth; Mark Laible; Jan C Brase; Ruprecht Kuner; Andreas Dahl; Christina Grimm; Behnam Sayanjali; Melanie Isau; Christina Röhr; Andrea Wunderlich; Bernd Timmermann; Rainer Claus; Christoph Plass; Markus Graefen; Ronald Simon; Francesca Demichelis; Mark A Rubin; Guido Sauter; Thorsten Schlomm; Holger Sültmann; Hans Lehrach; Michal R Schweiger
Journal:  Cancer Discov       Date:  2012-08-28       Impact factor: 39.397

4.  The polycomb group protein EZH2 is involved in progression of prostate cancer.

Authors:  Sooryanarayana Varambally; Saravana M Dhanasekaran; Ming Zhou; Terrence R Barrette; Chandan Kumar-Sinha; Martin G Sanda; Debashis Ghosh; Kenneth J Pienta; Richard G A B Sewalt; Arie P Otte; Mark A Rubin; Arul M Chinnaiyan
Journal:  Nature       Date:  2002-10-10       Impact factor: 49.962

5.  Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells.

Authors:  Jing Tan; Xiaojing Yang; Li Zhuang; Xia Jiang; Wei Chen; Puay Leng Lee; R K Murthy Karuturi; Patrick Boon Ooi Tan; Edison T Liu; Qiang Yu
Journal:  Genes Dev       Date:  2007-04-16       Impact factor: 11.361

6.  The Polycomb group protein EZH2 directly controls DNA methylation.

Authors:  Emmanuelle Viré; Carmen Brenner; Rachel Deplus; Loïc Blanchon; Mario Fraga; Céline Didelot; Lluis Morey; Aleyde Van Eynde; David Bernard; Jean-Marie Vanderwinden; Mathieu Bollen; Manel Esteller; Luciano Di Croce; Yvan de Launoit; François Fuks
Journal:  Nature       Date:  2005-12-14       Impact factor: 49.962

Review 7.  The epigenomics of cancer.

Authors:  Peter A Jones; Stephen B Baylin
Journal:  Cell       Date:  2007-02-23       Impact factor: 41.582

8.  Diverse somatic mutation patterns and pathway alterations in human cancers.

Authors:  Zhengyan Kan; Bijay S Jaiswal; Jeremy Stinson; Vasantharajan Janakiraman; Deepali Bhatt; Howard M Stern; Peng Yue; Peter M Haverty; Richard Bourgon; Jianbiao Zheng; Martin Moorhead; Subhra Chaudhuri; Lynn P Tomsho; Brock A Peters; Kanan Pujara; Shaun Cordes; David P Davis; Victoria E H Carlton; Wenlin Yuan; Li Li; Weiru Wang; Charles Eigenbrot; Joshua S Kaminker; David A Eberhard; Paul Waring; Stephan C Schuster; Zora Modrusan; Zemin Zhang; David Stokoe; Frederic J de Sauvage; Malek Faham; Somasekar Seshagiri
Journal:  Nature       Date:  2010-07-28       Impact factor: 49.962

9.  Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.

Authors:  R Bruce Montgomery; Elahe A Mostaghel; Robert Vessella; David L Hess; Thomas F Kalhorn; Celestia S Higano; Lawrence D True; Peter S Nelson
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

10.  Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer.

Authors:  Sooryanarayana Varambally; Qi Cao; Ram-Shankar Mani; Sunita Shankar; Xiaosong Wang; Bushra Ateeq; Bharathi Laxman; Xuhong Cao; Xiaojun Jing; Kalpana Ramnarayanan; J Chad Brenner; Jindan Yu; Jung H Kim; Bo Han; Patrick Tan; Chandan Kumar-Sinha; Robert J Lonigro; Nallasivam Palanisamy; Christopher A Maher; Arul M Chinnaiyan
Journal:  Science       Date:  2008-11-13       Impact factor: 47.728
View more
  3 in total

1.  Systematic analysis reveals molecular characteristics of ERG-negative prostate cancer.

Authors:  Qingyu Xiao; Yidi Sun; Albert Dobi; Shiv Srivastava; Wendy Wang; Sudhir Srivastava; Yuan Ji; Jun Hou; Guo-Ping Zhao; Yixue Li; Hong Li
Journal:  Sci Rep       Date:  2018-08-27       Impact factor: 4.379

2.  Kaiso, a transcriptional repressor, promotes cell migration and invasion of prostate cancer cells through regulation of miR-31 expression.

Authors:  Honghe Wang; Wei Liu; ShaNekkia Black; Omari Turner; Juliet M Daniel; Windy Dean-Colomb; Qinghua P He; Melissa Davis; Clayton Yates
Journal:  Oncotarget       Date:  2016-02-02

3.  KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC.

Authors:  Hung-Jung Wang; Mamata Pochampalli; Ling-Yu Wang; June X Zou; Pei-Shan Li; Sheng-Chieh Hsu; Bi-Juan Wang; Shih-Han Huang; Ping Yang; Joy C Yang; Cheng-Ying Chu; Chia-Ling Hsieh; Shian-Ying Sung; Chien-Feng Li; Clifford G Tepper; David K Ann; Allen C Gao; Christopher P Evans; Yoshihiro Izumiya; Chi-Pin Chuu; Wen-Ching Wang; Hong-Wu Chen; Hsing-Jien Kung
Journal:  Oncogene       Date:  2018-08-02       Impact factor: 9.867
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.